RESOURCE LIBRARY

Advancing medicine through scientific ingenuity

RESOURCE LIBRARY

Advancing medicine science through scientific ingenuity

At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.

Filter by

CLEAR
Monday, December 9, 2024
66th American Society of Hematology (ASH) Annual Meeting
Efficacy And Safety Of The Bruton’s Tyrosine Kinase (BTK) Degrader NX-5948 In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results From An Ongoing Phase 1A/B Study
Saturday, November 16, 2024
ACR Convergence 2024
NX-5948, A Clinical-Stage BTK Degrader, Achieves Deep Suppression Of BCR, TLR, And Fcr Signaling In Immune Cells And Demonstrates Efficacy In Preclinical Models Of Arthritis And Other Inflammatory Diseases
Friday, November 15, 2024
ACR Convergence 2024
IRAK4 Degrader GS-6791 Inhibits TLR And IL-1R-Driven Inflammatory Signaling, And Ameliorates Disease In A Preclinical Arthritis Model
Tuesday, October 29, 2024
7th Annual TPD & Induced Proximity Summit
An Orally Bioavailable, Brain Penetrant, Pan-Mutant BRAF Degrader For The Treatment Of Primary And Inhibitor-Resistant Solid Tumors
Saturday, October 19, 2024
12th International Workshop on Waldenstrom’s Macroglobulinemia
NX-5948: BTK Degrader with Activity in Lymphoid Malignancies
Tuesday, October 1, 2024
Discovery on Target
Rational Discovery Of A Small Molecule Intramolecular Glue Inhibitor Of CBL-B That Enhances T-Cell Function
Tuesday, October 1, 2024
Discovery on Target
The Evolving Chemical Space of Bi-functional Degraders Targeting the CNS
Monday, September 9, 2024
ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit
Targeted Protein Degraders As Next Generation Antibody Payloads
Wednesday, August 21, 2024
Fall 2024 ACS Meeting
A Rapid Matrix Approach For The Discovery Of Potent IRAK4 Targeted Protein Degraders
Sunday, June 16, 2024
European Hematology Association Congress (EHA2024)
Latest Results From An Ongoing First-In-Human Phase 1A/B Study Of NX-5948, A Selective Bruton’s Tyrosine Kinase (BTK) Degrader, In Patients With Relapsed/Refractory CLL And Other B-Cell Malignancies